Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 311 → 314 locations
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints: details revised at 2 of 12 entries
  2. Trial sites expanded: 286 → 311 locationsv5
  3. Trial sites expanded: 269 → 286 locationsv4
  4. Trial sites expanded: 258 → 269 locationsv3
  5. Trial sites expanded: 230 → 258 locationsv2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
729 trials monitored
See 62 trials at risk
Gastric Cancer
1,281 trials monitored
See 61 trials at risk
Esophageal Cancer
1,051 trials monitored
See 53 trials at risk
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Trial Details
NCT Number NCT07431281
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
Related terms Adenocarcinoma, Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms
Enrollment 2,130 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov